Beta
Bictegravir
medication Under reviewAn integrase strand transfer inhibitor (INSTI) used as part of antiretroviral therapy for HIV-1 infection.
Research summary
Clinical research on bictegravir centers on phase 3 trials evaluating fixed-dose combinations like bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and virologically suppressed adults with HIV-1. Studies consistently show high rates of viral suppression, with non-inferiority to comparator regimens, durable efficacy up to five years, and a favorable safety profile. No studies were identified specifically in healthy human subjects without HIV, as research focuses on HIV-infected populations; evidence in healthy volunteers is limited to pharmacokinetic interactions.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Research
No studies found yet. Request research to discover relevant studies.
Community updates
No updates yet for this supplement.
Be the first to share your experience!